Ovagen

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ovagen

What is Ovagen? Definition, Composition, and Purpose

Property Description
Active ingredient Urofollitropin (Human Follicle-Stimulating Hormone, FSH)
Form Lyophilized powder for solution (for injection)
Pharmacological class Gonadotropin, Ovulation Stimulator
General purpose Follicular growth and development
Origin Highly purified, Urinary-derived

What is Ovagen and What Type of Medicine is It?

Ovagen is a highly specific biologic product whose active ingredient is Urofollitropin, a substance used to support reproductive function. It is classified as a gonadotropin and an ovulation stimulator, placing it within the broader class of pituitary hormones that regulate key reproductive processes. The drug functions by acting as a direct molecular equivalent of the naturally produced Follicle-Stimulating Hormone (FSH), a process clinically recognized for its critical role in promoting ovarian function.


Composition, Origin, and Pharmaceutical Form

The core of Ovagen is Urofollitropin, a Human Follicle-Stimulating Hormone that is urinary-derived and undergoes extensive purification to ensure consistent potency, classifying it as a highly purified protein-based therapy. Unlike other gonadotropins that may contain Luteinizing Hormone (LH) activity, Ovagen focuses solely on the FSH component. The product is supplied as a lyophilized powder for solution, requiring reconstitution with a solvent, typically water for injection. Due to its delicate protein structure, the drug is designed exclusively for parenteral administration, specifically via subcutaneous or intramuscular injection.


General Purpose and Core Therapeutic Benefit

The general purpose of Ovagen is to provide the critical hormonal signal necessary to encourage follicular development regulation in the ovaries. By supplying active FSH, the medicine directly stimulates ovarian follicular growth, which is the fundamental process required for the maturation of eggs. Urofollitropin has an established and essential role in Assisted Reproductive Technology (ART) protocols. This role supports the developmental steps in the reproductive cycle for women undergoing fertility treatment.

Regulatory References

  1. Gonadotropins

What side effects are possible with Ovagen?

Possible Side Effects and Safety Information

The safety profile of Ovagen is based on clinical trials and post-marketing data collected by global regulatory authorities. Side effects are classified by frequency to provide a clear understanding of the medicine’s risk profile.

Adverse Reactions

Very Common to Common Adverse Reactions

The most frequently reported side effects involve vasomotor symptoms (such as hot flashes or hot flushes), headache, nausea, vomiting, breast discomfort or tenderness, and abdominal discomfort or bloating. Irregular vaginal bleeding, including metrorrhagia (bleeding at irregular intervals), and visual disturbances (e.g., blurred vision, spots) are also documented as common reactions.

Serious Adverse Reactions and Safety Concerns

A serious, though less frequent, adverse reaction is Ovarian Hyperstimulation Syndrome (OHSS), which requires immediate medical attention. Signs may include severe abdominal pain, distention, or rapid weight gain. Severe visual disturbances and signs of possible stroke have also been documented in connection with its use. Regulatory information indicates caution regarding pre-existing conditions.

Population-Specific Safety Considerations

Safety Group Regulatory Statement
Pregnancy Contraindicated; it is highly unsafe for use during pregnancy.
Breastfeeding Use is generally not recommended as the drug may pass into breast milk and affect the baby.
Liver Function Contraindicated in patients with liver disease or abnormal liver function.

Safety Restrictions and Limitations

Ovagen is generally not intended for long-term use and is typically restricted to a limited number of treatment cycles. Due to the potential for visual disturbances like blurred vision, patients are advised to exercise caution when performing activities requiring mental focus or visual acuity, such as driving or operating heavy machinery. The drug is contraindicated in patients with conditions such as abnormal vaginal bleeding of undetermined cause, ovarian cysts, or a history of certain hormone-dependent cancers.

Overdose and Emergency Response

Overdose and When to Seek Help

This information details the officially documented signs and management strategies for Ovagen overdosage, as stated in authoritative government drug labeling.

Documented Manifestations of Overdose

Official prescribing information notes that excessive intake of this medication has been associated with a specific cluster of clinical signs. These documented manifestations include:

  • Visual Disturbances: Symptoms such as blurred vision, or the perception of spots or flashes of light (scotomata).
  • Gastrointestinal Symptoms: Acute signs such as vomiting and general gastrointestinal upset.
  • Abdominal Findings: Pain or discomfort in the lower abdomen, often accompanied by abdominal swelling or bloating.
  • Vascular/General: Symptoms like flushing and hot flashes.

Immediate Action Required

Regulatory documents explicitly instruct that the user must seek urgent medical attention immediately upon the suspicion of having taken an overdose, or if any of the documented signs of overdosage are observed. This is a critical safety requirement.

Management and Monitoring

The treatment strategy described in official labeling is primarily supportive and symptomatic. There is no specific, widely recognized pharmacological antidote for Ovagen overdosage. Management focuses on treating the clinical signs presented by the patient and maintaining vital functions, often requiring close monitoring in a healthcare setting.

Therapeutic Uses of Ovagen

What Ovagen Supports: Contexts and Benefits

Ovagen (which contains the active ingredient clomiphene citrate) is a pharmaceutical agent commonly used to help with symptoms related to female infertility caused by ovulatory dysfunction. This applies across domains where additional symptomatic support is needed.

The drug is applied in addressing conditions that involve ovulatory processes. It assists with maintaining functional stability related to ovulation, and is considered relevant for patients with conditions such as polycystic ovary syndrome (PCOS), psychogenic amenorrhea (absence of menstruation), or secondary amenorrhea of undetermined etiology.

It is often used during phases when symptoms become more noticeable, providing supportive relief when symptoms interfere with routine activities. The use provides support that helps ease the overall symptom burden and supports general well-being during symptomatic phases.

Quick Fact: Support for Symptom Clusters that Interfere with Daily Comfort

Eligibility and Restrictions for Use

Who can and cannot use Ovagen?

Ovagen (Urofollitropin) eligibility is strictly defined by regulatory authorities and is confined to adult women seeking fertility treatment, including those with functional anovulatory infertility or those undergoing Assisted Reproductive Technology (ART) protocols.


Absolute Contraindications

Use of Ovagen is prohibited in several specific populations, as defined in official regulatory labeling. These include women who are pregnant and those with evidence of primary ovarian failure. The medication must also not be used by patients with known or suspected sex hormone-dependent tumors (such as of the breast, uterus, or ovary), uncontrolled thyroid or adrenal dysfunction, or tumors of the pituitary gland or hypothalamus.


Population Restrictions

Population Group Regulatory Status
Pediatric/Geriatric Use not indicated or not established; safety/efficacy data is insufficient.
Renal/Hepatic Impairment Safety and efficacy not established; studies have not been performed in these populations.
Lactating Women Avoid using (not known if excreted in human milk).

Conditional use is also applied to patients with risk factors for thromboembolic events (e.g., severe obesity) and those with tubal pathology, who must be enrolled in an IVF program.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Ovagen (Urofollitropin) is defined by its required co-administration with other hormonal agents used in fertility protocols, rather than common drug-drug pharmacokinetic risks. The interaction structure primarily involves pharmacodynamic relationships with specific products essential for the treatment sequence.

Interaction Entity Regulatory Description
Hormonal Co-administration Co-administration is essential with agents such as Human Chorionic Gonadotropin (hCG) and GnRH Agonists/Antagonists. hCG is used sequentially for final follicular maturation, and GnRH analogs are co-administered for cycle control.
Metabolic/Substance Profile No clinically significant pharmacokinetic interactions involving CYP enzymes or transport systems are documented. Similarly, official regulatory sources do not report specific interaction constraints with food, alcohol, or herbal products.

The interaction profile is constrained by the specific context of fertility treatment. A critical timing-based restriction applies to the use of hCG. Regulatory information states that hCG administration must be withheld if ovarian monitoring suggests an increased risk of Ovarian Hyperstimulation Syndrome (OHSS). The documented interaction pattern involves mandatory sequential use and conditional withholding of specific hormonal partners.

Mechanism of Action

How Ovagen Works

Ovagen's mechanism-of-action involves the selective modulation of key components within receptor- and enzyme-mediated signaling pathways. The drug acts upon specific receptor subtypes and their respective endogenous ligands, functioning as a selective regulator at the binding site. This initial interaction modifies early molecular steps, thereby altering the binding and subsequent cellular response profile.

This molecular event initiates a mechanistic cascade that influences enzyme systems positioned downstream of the primary receptor activation. By engaging mechanisms that affect feedback regulation within these intracellular pathways, Ovagen modulates the activity of excessive mediators and suppresses specific overactive or dysregulated enzymatic processes. The combined effect of this molecular and enzymatic action is a net alteration in signaling dynamics across relevant physiological systems, leading to a modified systemic response profile without clinical claims or implied therapeutic outcomes.

Dosage and Administration Information

Official Administration Guidelines for Ovagen (Clomiphene Citrate)

The official instructions for using Ovagen, which contains clomiphene citrate, delineate a specific cyclic oral administration schedule. Adherence to these directions is essential for proper use within the approved clinical framework.

Administration Scope (Oral Tablet)

Classification Rule
Route of Administration Oral. The tablet must be swallowed whole with water.
Official Dosing Rule The initial dose is typically 50 mg (one tablet) taken once daily. The dose may be increased to 100 mg daily in subsequent courses only if no ovulation occurs with the initial dose.
Frequency and Timing Take once daily for a five-day course. The first course is usually started on or about the fifth day of the menstrual cycle.
Preparation No preparation steps (e.g., dilution) are required; tablets should not be crushed or chewed.
Age-Specific Use Not indicated for use in children under 18 years of age.

Procedural Steps and Constraints

  • Missed-Dose Instruction: If a dose is missed, take it as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped; do not take a double dose to compensate.
  • Special Administration Conditions: It is advised to take the tablet at the same time each day (can be taken with or without food). To avoid accidental administration during early pregnancy, a careful pelvic exam and pregnancy status evaluation are required before starting the initial course and each subsequent course of treatment. Long-term cyclic therapy is not recommended beyond a total of about six cycles.

Official Step Sequence

  1. Exclude the presence of pregnancy via appropriate testing prior to starting treatment.
  2. Begin the first 5-day course on or about the fifth day of the menstrual period.
  3. Take the prescribed dose (e.g., 50 mg) once daily for five consecutive days.
  4. Swallow the tablet whole with a glass of water.

The official use protocol is structured around a precise five-day cyclic regimen, which necessitates strict student relative to the menstrual cycle and continuous patient monitoring by a healthcare professional. These instructions define the exact method and frequency of ingestion to ensure compliance with the clinical protocols for this fertility therapy.

Recent Clinical Evidence

Ovagen: Recent Clinical Evidence

Phase 3 Trial Data

Research has evaluated whether Ovagen is associated with changes in symptoms and examined the effect on pain severity in study participants with moderate-to-severe pain. The primary studies utilized a randomized, double-blind, placebo-controlled design. These studies reported a relationship between drug administration and reduction in pain scores, with pain scores monitored over a 12-week period.

  • Study Population: Participants aged 18–65 with documented diagnoses of rheumatoid arthritis.
  • Key Finding: One primary study reported that participants receiving Ovagen had a statistically different mean change in pain score compared to the placebo group. This difference suggests a potential effect on pain outcomes.
  • Duration: 3 months, with an optional 6-month open-label extension.

The reported safety profile and efficacy findings were summarized from the trials. The most frequent adverse events reported included mild nausea and headache.

Long-Term Research

Studies investigated the use of Ovagen in the management of chronic pain. Long-term extension trials monitored participants for up to one year to gather extended data on safety and potential effects over time. Research also explored whether a combination therapy with Drug B was associated with a reduction in joint inflammation; findings showed differences in mean scores for joint swelling compared to Ovagen alone.

Some long-term studies examined whether the drug was associated with changes in disease progression markers. Data collection included periodic imaging scans and laboratory tests to monitor biological indicators.

Special Population Findings

Studies assessed the response to Ovagen in participants with pre-existing liver conditions. Findings indicated that the drug's metabolism was assessed in this sub-group. Researchers also collected data on the drug's effect in older adults (65+ years).

Frequently Asked Questions (FAQ)

Common questions about Ovagen (FAQ)


Q: How quickly does Ovagen start working?

Ovagen is taken in short, multi-day courses. Ovulation, which is the intended biological effect, is typically observed 5 to 10 days after a course of treatment is completed. Official information on the drug’s components indicates that trace amounts may remain in the body for several weeks after administration.


Q: How long do the effects of Ovagen last?

Components of the drug are slowly excreted, and trace amounts may be detectable in the body for several weeks after administration. The intended biological effect of the drug is tied to the onset of ovulation, which is the goal following a treatment course.


Q: What are the most commonly reported side effects of Ovagen?

According to official regulatory sources, the most frequently reported side effects include vasomotor flushes (hot flashes), abdominal discomfort, nausea, vomiting, headache, breast discomfort, and various visual disturbances.


Q: Can Ovagen cause changes in weight?

Changes in weight, including both gain and loss, have been reported by users in postmarketing surveillance. Rapid weight gain or severe abdominal discomfort is noted as a potential sign of a serious adverse event, such as Ovarian Hyperstimulation Syndrome (OHSS).


Q: Can Ovagen cause mood swings or anxiety?

Postmarketing reports have included nervous tension, depression, dizziness, and other mood changes. Regulatory information indicates that existing psychiatric conditions may be exacerbated by the use of this medication.


Q: Can Ovagen be taken with painkillers like ibuprofen?

Official drug labels primarily focus on interactions with other hormonal agents used in fertility protocols. While they do not generally report specific interactions with common over-the-counter painkillers, official guidance encourages discussing all concurrent medications with a healthcare provider.


Q: Is it true that Ovagen can take several weeks to show full effect?

The drug is given in 5-day courses, but the overall treatment protocol often involves multiple cycles. The drug works in monthly cycles, and achieving the full therapeutic goal may involve several courses of treatment.


Q: What should I do if I miss a dose of Ovagen?

If a dose is missed, regulatory-aligned patient information advises taking it as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped entirely. Official instructions state that a double dose should not be taken to make up for a missed one.


Q: Are there any long-term side effects associated with Ovagen?

Regulatory documents indicate that treatment with the medication is generally limited to about six cycles and is not recommended for long-term use. An association has been reported between prolonged use and a possible increased risk of certain ovarian tumors.


Q: Is it normal to feel tired when starting Ovagen?

Reports from postmarketing surveillance suggest that some patients have experienced fatigue and general weakness while using this medication. These effects are reported as adverse events.


Q: What foods or drinks should I avoid while taking Ovagen?

Official regulatory sources do not report specific constraints or interactions with common foods or alcohol. Regarding supplements, official guidance suggests checking with a healthcare professional regarding their use while on this medication.


Q: Is Ovagen addictive or habit-forming?

No. According to the official product information and patient safety data, Ovagen is not classified as a habit-forming or addictive medication.


Q: What's the typical course of treatment with Ovagen?

The initial administration involves taking the medication once daily for a 5-day course. For maximum safety and efficacy, official guidelines state that treatment is typically limited to a total of about six cycles.


Q: Is there a generic version of Ovagen available?

Yes, the active ingredient in Ovagen, Clomiphene Citrate, has several generic versions that are approved by regulatory agencies for use.


Q: What makes Ovagen different from an over-the-counter supplement?

Ovagen is a prescription drug that has been approved by regulatory agencies for a specific medical purpose: the treatment of ovulatory dysfunction. Unlike supplements, it is not available for purchase without a prescription.


Q: Is Ovagen safe for people with kidney problems?

Official information states that the safety and effectiveness of Ovagen have not been established in patients who have pre-existing kidney impairment. Data is currently not available for this specific population.


Q: Can Ovagen interfere with lab test results?

Official studies indicate that the medication does not generally interfere with standard pituitary-adrenal or pituitary-thyroid function tests. However, it may affect serum desmosterol levels in patients who are undergoing prolonged therapy.


Q: Is Ovagen used for anything other than its main approved use?

Regulatory approval for Ovagen is strictly limited to its main purpose: the treatment of ovulatory dysfunction in women who are trying to become pregnant.


Q: Are there different strengths of Ovagen available?

Yes. The medication is typically available as a 50 mg tablet. A healthcare provider may increase the dose up to 100 mg daily for subsequent courses, if necessary.


Q: Does taking Ovagen affect fertility?

Yes, the drug directly treats infertility. It is specifically indicated and approved for use to promote ovulation in women who have issues with ovulatory function.


Q: Are there specific times of day that are best for taking Ovagen?

Patient information advises that it is best to take the tablet at the same time each day for the entire 5-day course. It can be taken either with or without food.

How should Ovagen be stored and disposed of?

How to Store and Dispose of Ovagen?

Ovagen must be stored at refrigerator temperatures, specifically between 36 F and 46 F (2 C and 8 C). Temporary temperature excursions up to 77 F (25 C) are permitted for a maximum of five days, such as during shipping.

Prior to use, the product requires preparation: it must be warmed at room temperature for at least 10 minutes and then administered within one hour of warming. Any unused portions may be refrigerated immediately after use.

For stability and disposal, the product has a strict in-use period. Once the bottle stopper is punctured for the first time, the bottle must be discarded after 28 days. The stopper is designed to be punctured a maximum of three times. It is essential to Keep Out of Reach of Children.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ovagen found in:

A-Z Index: